TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18371200
Drug: Likelihood of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Likelihood of reporting harm in the abstract when funded by drug companies
Study: 12810489
Drug: Rivastigmine 6‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 6‐ to 12‐mg/d
Study: 8779365
Drug: Ephedrine 0.1
Normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.1 mg.kg‐1
Study: 2022674
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 4% during daily dressing changes
Study: 30451718
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education by a clinical pharmacist on correct patch administration
Study: 16801302
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (exact dosage and duration not specified)
Study: 12766829
Drug: Estriol-containing vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol-containing vaginal pessary (0.5 mg estriol) twice weekly
Study: 12766829
Drug: Nitrofurantoin macrocrystal
Normalized name: Nitrofurantoin macrocrystal
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin macrocrystal (100 mg) once daily
Study: 1498532
Drug: gu chi
Normalized name: Gu
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gu chi wan (tooth firming pills) 4 mg twice daily for 3‐6 months combined with spiramycin 0.2 four times daily for 5 days and routine periodontal treatment
Study: 1498532
Drug: spiramycin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: spiramycin 0.2 four times daily for 5 days combined with routine periodontal treatment
Study: 1498532
Drug: gu chi
Normalized name: Gu
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gu chi wan (tooth firming pills)
Study: 3701513
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy (experimental group)
Study: 3701513
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy (iron-deficient not anemic group, n = 22)
Study: 28646940
Drug: Intradetrusor injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor injection of botulinum toxin type A (BTX‐A) 100 U
Study: 28646940
Drug: Intradetrusor injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor injection of botulinum toxin type A (BTX‐A)
Study: 27163420
Drug: Diltiazem infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem infusion (2.5 microgram/kg/min)
Study: 27163420
Drug: No diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diltiazem infusion
Study: 11841884
Drug: Diltiazem infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem infusion
Study: 15093845
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac tromethamine (0.5 mg/kg, max 30 mg)
Study: 9048403
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg/day continued prophylaxis, N = 90
Study: 27084247
Drug: High-dose CVVHDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CVVHDF (80mL/kg/h)
Study: 27084247
Drug: Conventional-dose CVVHDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CVVHDF (40mL/kg/h)
Study: 25026897
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: 3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 200 mg/m2 followed by 3 cycles of intensified CMF
Study: 25026897
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: 3 cycles of epirubicin followed by 3 cycles of CMF, then 9 weekly cycles of docetaxel 35 mg/m2
Study: 25026897
Drug: Arm C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C: 9 weekly cycles of paclitaxel 80 mg/m2
Study: 16831228
Drug: Low basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low basic antibody titre against influenza
Study: 10703660
Drug: Supra-gingival oral
Normalized name: Supra Sulfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supra-gingival oral irrigation plus routine oral hygiene (ROH) for 14 days
Study: 10703660
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral hygiene (ROH) for 14 days
Study: 10703660
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral hygiene for 14 days
Study: 26625939
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy protocol with supervised usage of adaptive devices (n=20)
Study: 26625939
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (n=20)
Study: 22369176
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment containing a seaweed-derived oligosaccharide complexed with 0.1% zinc pyrrolidone
Study: 10408405
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1000 mg m‐2 intravenous (i.v.) weekly for 3 weeks out of every 4 and 5‐fluorouracil (5‐FU) 600 mg m‐2 bolus i.v. weekly for 3 weeks out of every 4
Study: 7551201
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with high doses of Parietaria extract (cumulative dose of 105 BU)
Study: 1763422
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training for remembering names and faces (treatment duration: one month, twice weekly)
Study: 29847188
Drug: Combined MLD
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined MLD and vibrotherapy treatment
Study: 22415479
Drug: Suboptimal 25OHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal 25OHD (<72 nmol/l)
Study: 22415479
Drug: 25OHD, insulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25OHD, insulin, CRP, and leptin levels as continuous variables
Study: 19329013
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL normal saline (control group)
Study: 12174106
Drug: Azathioprine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2.5 mg kg(‐1) day(‐1)
Study: 9400430
Drug: 1 gm.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm. mycophenolate mofetil twice daily
Study: 9400430
Drug: 1.5 gm.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 gm. mycophenolate mofetil twice daily
Study: 729378
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive with synthetic estrogen (ethinyl estradiol)
Study: 729378
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive with natural estrogens (micronized estradiol and estriol)
Study: 28437539
Drug: Low-dose valganciclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valganciclovir hydrochloride (n=46)
Study: 21157026
Drug: Galantamine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (16 to 24 mg/day)
Study: 19692371
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib (IVP) 0.3 mg every 6 weeks for 30 weeks
Study: 14724039
Drug: 50‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50‐mg oral naltrexone
Study: 11431296
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (12.5 mg zinc sulphate daily for six days a week for six months)
Study: 9741901
Drug: New sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sustained-release formulation of amoxicillin (500 mg)
Study: 9741901
Drug: Conventional gelatin
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gelatin capsule of amoxicillin (500 mg)
Study: 8285810
Drug: Comparison drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison drug
Study: 29604311
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing silicone particles
Study: 29604311
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing Microsponge® particles (control)
Study: 20863241
Drug: Surface preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface preparation with 37% phosphoric acid for 30 s
Study: 20863241
Drug: Surface preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface preparation with 0.5‐W Er,Cr:YSGG laser for 6 s
Study: 18353086
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface preparation
Study: 20863241
Drug: Conventional bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bleaching procedure (without surface preparation)
Study: 18851795
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg/m2)
Study: 18851795
Drug: Glutamine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (1500 mg/m2)
Study: 3306904
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg nocte)
Study: 29354971
Drug: Flipping moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flipping moxibustion of Hui medicine combined with western medication
Study: 29354971
Drug: Simple western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple western medication (oral methotrexate and sulfasalazine)
Study: 25701866
Drug: Daily proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily proguanil
Study: 22476119
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg bid for 7 days
Study: 22476119
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg bid for 7 days (excluding Child-Pugh A and patients without ascites)
Study: 18236372
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg immediately following surgery and four days postoperatively)
Study: 18236372
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CSA, adapted to blood-trough level 120-150 ng/mL for six months)
Study: 12679436
Drug: Ghrelin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (1.0 micro g/kg iv)
Study: 9364537
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2, intravenous infusion for 1 hour once every 3 weeks)
Study: 9364537
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m2, intravenous infusion for 15 to 20 minutes once every 3 weeks)
Study: 31561652
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (20 mL) only (group B)
Study: 31561652
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% + 10 mg morphine (group BM10)
Study: 31561652
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% + 15 mg morphine (group BM15)
Study: 27364096
Drug: Diphtheria, tetanus,
Normalized name: Diphtheria, Tetanus, Poliomyelitis adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria, tetanus, and polio booster vaccines
Study: 22472339
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (0.4 mg daily)
Study: 18727841
Drug: r‐hFSH and
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hFSH and r‐hLH (all doses)
Study: 10665496
Drug: CP-122,288 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-122,288 (doses between 3.125 and 312.5 microg orally)
Study: 9313057
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered intravenously (200 to 400 mg) or orally (500 to 750 mg) twice a day for 6 to 21 days
Study: 8317647
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ginger
Study: 31969155
Drug: Maternal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal treatment with primaquine
Study: 26472297
Drug: Sham TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TENS treatment sessions (control group)
Study: 23186260
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 5% i.u. infusion (140 ml)
Study: 23186260
Drug: Saline i.u.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline i.u. infusion (140 ml)
Study: 20693158
Drug: gemfibrozil, niacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil, niacin, and cholestyramine in combination
Study: 18325911
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (IV) - received staff asthma training, advice on asthma policy, emergency beta(2)-agonist inhaler with spacer, and asthma lesson
Study: 9377615
Drug: Hydrocortisone buteprate
Normalized name: Hydrocortisone buteprate
DrugBank: Hydrocortisone probutate (DB14543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone buteprate 0.1% cream
Study: 24442048
Drug: Nutraceutical (Q10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical (Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E, selenium) in addition to etanercept therapy
Study: 24442048
Drug: Etanercept therapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept therapy alone
Study: 18502911
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (intended six months of continued conservative treatment)
Study: 16574893
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg torcetrapib once daily for 4 weeks
Study: 16574893
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg torcetrapib twice daily for an additional 4 weeks (nonatorvastatin group)
Study: 16574893
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg torcetrapib on a background of atorvastatin
Study: 11789169
Drug: 1000 ml
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Study: 11789169
Drug: XQN 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: XQN 5‐10 tablets 3 times per day combined with 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Study: 11789169
Drug: Coated aldehyde
Normalized name: lauryl aldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated aldehyde oxystarch 5‐10 g, 3 times a day
Study: 8455235
Drug: Intravesical bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacillus Calmette-Guerin (BCG) administration
Study: 3523636
Drug: Ornidazole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole (2.5 g/m2, administered orally, two times weekly for 3 weeks, total dose 15 g/m2)
Study: 3523636
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered orally, two times weekly for 3 weeks)
Study: 23410186
Drug: Phenylephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (50 to 100 μg)
Study: 23410186
Drug: Ephedrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (5 to 10 mg)
Study: 17118491
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum (sugar-free or regular) for 15 min hourly after lunch
Study: 15789977
Drug: Oral‐B Indicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Indicator
Study: 12518488
Drug: Oral‐B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B CrossAction
Study: 11169936
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2 on Day 1) plus Vinorelbine (25 mg/m2 on Days 1 and 8, every 3 weeks for a minimum of 3 cycles)
Study: 11169936
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2/week for a minimum of 9 weeks)
Study: 26275653
Drug: Chlorella vulgaris
Normalized name: CHLORELLA VULGARIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella vulgaris extract (CVE) 1800 mg/day
Study: 26275653
Drug: Standard antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressant therapy alone (Control)
Study: 23219636
Drug: High-dose, high-repetition
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, high-repetition medical exercise therapy
Study: 23219636
Drug: Low-dose, low-repetition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, low-repetition exercise therapy
Study: 21986283
Drug: LCI699 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 1.0 mg once daily
Study: 21986283
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of LCI699
Study: 17326594
Drug: AVINZA (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVINZA (morphine sulfate extended-release capsules) once a day
Study: 17326594
Drug: OxyContin (oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxyContin (oxycodone controlled-release tablets) twice a day
Study: 12718385
Drug: Doxorubicin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (30 mg)
Study: 12718385
Drug: Mitoxantrone (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (14 mg)
Study: 9548208
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg daily)
Study: 11855793
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg daily)
Study: 1606094
Drug: 10-mg intravenous
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg intravenous metoclopramide
Study: 31164067
Drug: 60 hours
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 hours of therapy
Study: 31164067
Drug: 0 hours
Normalized name: nicotine 0.583 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 hours of therapy
Study: 31164067
Drug: 15 hours
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 15 hours of therapy
Study: 31164067
Drug: 30 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 hours of therapy
Study: 25194106
Drug: 540 mL
Normalized name: ALCOHOL 540 mL in 750 mL TOPICAL GEL [Wonder Hand Gel (Ethanol)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 540 mL bladder-filling protocol
Study: 25194106
Drug: 1080 mL
Normalized name: pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1080 mL bladder-filling protocol
Study: 20385892
Drug: Glycopyrrolate 1
Normalized name: glycopyrrolate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 1 mg 3 times daily
Study: 8035933
Drug: Entacapone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (400 mg or 800 mg)
Study: 8035933
Drug: Carbidopa (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (150 mg) plus placebo
Study: 8035933
Drug: Carbidopa (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (150 mg) plus entacapone (400 mg or 800 mg)
Study: 2564109
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5-fluorouracil and mitomycin C with or without induction course of 5-fluorouracil, vincristine, cyclophosphamide, and methotrexate)
Study: 4772727
Drug: Benzhexol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzhexol (8 mg/day)
Study: 29216779
Drug: Placebo (21.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (21.6% hydro-alcohol solution)
Study: 27475733
Drug: Adjusted heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted heparin regimen
Study: 27475733
Drug: Traditional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional heparin regimen
Study: 17971121
Drug: Two axial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two axial grooves added to the crown preparation
Study: 17971121
Drug: One axial
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One axial groove added to the crown preparation
Study: 12810695
Drug: High-dose bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bolus interleukin-2 (IL-2) at a dosage of 600,000 U/kg every 8 hours on days 1 to 5 and days 15 to 19 (maximum 28 doses)
Study: 12810695
Drug: High-dose bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bolus interleukin-2 (IL-2)
Study: 26464863
Drug: Rhubarb supplementation
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb supplementation (350mg, thrice daily for 12 weeks)
Study: 17403173
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid 10 mg 3 times a week immediately after every dialysis session
Study: 17403173
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid
Study: 2095342
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of Salbutamol
Study: 873029
Drug: Tetrabid-Organon (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabid-Organon (standard therapeutic doses)
Study: 25996468
Drug: Facial‐Oral Tract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial‐Oral Tract Therapy (F.O.T.T.)
Study: 19367397
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5,000 Units twice daily
Study: 19367397
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) enoxaparin 40 mg per day